TY - JOUR
T1 - Preimplantation Genetic Screening (PGS) with Comparative Genomic Hybridization (CGH) following day 3 single cell blastomere biopsy markedly improves IVF outcomes while lowering multiple pregnancies and miscarriages
AU - Keltz, Martin D.
AU - Vega, Mario
AU - Sirota, Ido
AU - Lederman, Matthew
AU - Moshier, Erin L.
AU - Gonzales, Eric
AU - Stein, Daniel
PY - 2013/10
Y1 - 2013/10
N2 - Purpose: To determine benefits of cleavage-stage preimplantation genetic screening (PGS) by array comparative genomic hybridization (CGH). Methods: A retrospective case-control study was performed at a tertiary care university-affiliated medical center. Implantation rate was looked at as a primary outcome. Secondary outcomes included clinical and ongoing pregnancy rates, as well as multiple pregnancy and miscarriage rates. Thirty five patients underwent 39 fresh cycles with PGS by aCGH and 311 similar patients underwent 394 invitro fertilization cycles. Result(s): The implantation rate in the CGH group doubled when compared to the control group (52.63 % vs. 19.15 %, p = <0.001), clinical pregnancy rate was higher (69.23 % vs. 43.91 %, p = 0.0002), ongoing pregnancy rate almost doubled (61.54 % vs. 32.49 %, p = <0.0001), multiple pregnancy rate decreased (8.33 % vs. 34.38 %, p = 0.0082) and miscarriage rate trended lower (11.11 % vs. 26.01 %, p = 0.13). Conclusion: Cleavage stage PGS with CGH is a feasible and safe option for aneuploidy screening that shows excellent outcomes when used in fresh cycles. This is the first report of cleavage stage PGS by CGH showing improved ongoing pregnancy rates.
AB - Purpose: To determine benefits of cleavage-stage preimplantation genetic screening (PGS) by array comparative genomic hybridization (CGH). Methods: A retrospective case-control study was performed at a tertiary care university-affiliated medical center. Implantation rate was looked at as a primary outcome. Secondary outcomes included clinical and ongoing pregnancy rates, as well as multiple pregnancy and miscarriage rates. Thirty five patients underwent 39 fresh cycles with PGS by aCGH and 311 similar patients underwent 394 invitro fertilization cycles. Result(s): The implantation rate in the CGH group doubled when compared to the control group (52.63 % vs. 19.15 %, p = <0.001), clinical pregnancy rate was higher (69.23 % vs. 43.91 %, p = 0.0002), ongoing pregnancy rate almost doubled (61.54 % vs. 32.49 %, p = <0.0001), multiple pregnancy rate decreased (8.33 % vs. 34.38 %, p = 0.0082) and miscarriage rate trended lower (11.11 % vs. 26.01 %, p = 0.13). Conclusion: Cleavage stage PGS with CGH is a feasible and safe option for aneuploidy screening that shows excellent outcomes when used in fresh cycles. This is the first report of cleavage stage PGS by CGH showing improved ongoing pregnancy rates.
KW - Aneuploidy
KW - Blastomere biopsy
KW - Comparative genomic hybridization
KW - Preimplantation genetic screening
UR - http://www.scopus.com/inward/record.url?scp=84887996263&partnerID=8YFLogxK
U2 - 10.1007/s10815-013-0070-6
DO - 10.1007/s10815-013-0070-6
M3 - Article
C2 - 23949213
AN - SCOPUS:84887996263
SN - 1058-0468
VL - 30
SP - 1333
EP - 1339
JO - Journal of Assisted Reproduction and Genetics
JF - Journal of Assisted Reproduction and Genetics
IS - 10
ER -